Severe Acne

Fixed-dose triple combination CAB gel showed efficacy in treating acne in both male and female patients aged 9 years and older, according to pooled data from two studies.

Fixed-dose clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1% gel demonstrated safety and efficacy across all age groups for the treatment of acne, according to a post hoc analysis.

Isotretinoin is associated with a clinically marginal increased risk for severe adverse events, leading researchers to advise routine blood testing commence shortly after initiation, according to a study.

Topical triple-agent fixed-dose combination gel outperformed other treatment options for moderate to severe acne, according to a study.

The American Academy of Dermatology has released new care guidelines for acne vulgaris, according to a press release.

The FDA’s approval of IDP-126 was the most read Healio acne story this year, followed by coverage of a study finding IDP-126 improves patients’ quality of life compared to vehicle. News regarding the efficacy of M-PDT and clascoterone cream, as well as an update to the FDA’s iPledge recommendations, rounded out 2023’s important acne updates.

Newly FDA-approved IDP-126 gel improved quality of life outcomes in patients with acne vulgaris over vehicle, according to a study.

IDP-126 gel, which is a combination of clindamycin, adapalene and benzoyl peroxide, showed positive results in patients with moderate to severe acne, according to a study.

A combination of microencapsulated benzoyl peroxide and microencapsulated tretinoin significantly reduced inflammatory and noninflammatory lesions in patients with moderate to severe acne vulgaris, according to two phase 3 trials.

Isotretinoin produces a lower risk of six psychiatric comorbidities, as well as comparable risk of suicidal attempts, compared with other oral antibiotics in the treatment of severe acne, according to study findings.